(Q30368699)

21 June 2017

Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. (English)

1 reference

21 June 2017

0 references

1 reference

1 reference

David H Holman

1

1 reference

21 June 2017

Danher Wang

2

1 reference

21 June 2017

Nicholas U Raja

3

1 reference

21 June 2017

Min Luo

4

1 reference

21 June 2017

Kevin M Moore

5

1 reference

21 June 2017

Jan Woraratanadharm

6

1 reference

21 June 2017

Nutan Mytle

7

1 reference

21 June 2017

John Y Dong

8

1 reference

21 June 2017

language of work or name

English

0 references

publication date

14 March 2008

1 reference

21 June 2017

1 reference

21 June 2017

26

1 reference

21 June 2017

2627-2639

1 reference

21 June 2017

21

1 reference

Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Characterization of the 1918 influenza virus polymerase genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Initial genetic characterization of the 1918 "Spanish" influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Avian flu: influenza virus receptors in the human airway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.053

10.1016/J.VACCINE.2008.02.053

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference